MedTrace Logo

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

NCT04182516 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2024-09-19

No results posted yet for this study

Summary

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.

Conditions

  • Advanced/Metastatic Solid Tumors

Interventions

DRUG

NMS-03305293

All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles.

Sponsors & Collaborators

  • Nerviano Medical Sciences

    lead INDUSTRY

Principal Investigators

  • Valentina Guarneri, MD · Istituto Oncologico Veneto IRCCS

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-25
Primary Completion
2023-03-31
Completion
2024-05-16
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • China
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04182516 on ClinicalTrials.gov